Enrolment for the second Statin Response Examined by Genetic Hap™ Markers trial

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1322, 2002-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Alexza Pharmaceuticals has announced that it has completed enrolment in its second phase III trial with loxapine

By  

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Survey gives insight into ICU clinical trial enrolment

By  

Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Statin response and pharmacokinetics variants

By Kajinami Kouji   Masuya Hiroshi   Hoshiba Yachiyo   Takeda Kenji   Sato Ryoko   Okabayashi Mizuho   Schaefer Ernst J  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 8, 2005-07 ,pp. : 1291-1297

Informa Healthcare

Access to resources Recommend Favorite

Second Phase of HapMap project completed

By  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1489-1491

Future Medicine

Access to resources Recommend Favorite

Genetic cause identified for statin-induced muscle pain

By  

Pharmacogenomics, Vol. 9, Iss. 1, 2008-01 ,pp. : 11-13

Future Medicine

Access to resources Recommend Favorite